March 27th 2024
“These results are encouraging and suggest that circulating biomarkers may be useful in guiding the use of radium-223 therapy,” says David T. Miyamoto, MD, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix now available in Canada for advanced prostate cancer
March 13th 2024"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.
Agents show potential to bolster precision medicine in prostate cancer
March 12th 2024"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.
Enrollment complete in phase 2 study of PT-112 in mCRPC
March 8th 2024"We are confident in PT-112's potential as an effective treatment for patients with mCRPC who have progressed on androgen receptor directed therapy, chemotherapy or radioligand therapy and who lack any effective immunotherapy," says Robert Fallon.
ArteraAI Prostate Test included in NCCN guidelines
March 5th 2024“This significant milestone not only celebrates ArteraAI's success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care," says Andre Esteva.
Dr. Tewari on the launch of a mobile prostate cancer screening unit
February 21st 2024“My goal was very simple. Five years from now, there will be X number of more fathers, brothers, grandfathers who will be having dinners with their families because of what I'm doing, because I will find the cancer early and hopefully make an impact,” says Ashutosh Tewari, MD.
OS benefit with darolutamide maintained throughout mHSPC treatment course
February 19th 2024"Post-hoc sensitivity analyses from the phase 3 ARASENS trial presented at ASCO GU were consistent with and supportive of the ARASENS primary OS analysis–reinforcing darolutamide plus ADT plus docetaxel as an effective and well tolerated standard of care in patients with mHSPC," writes Neal Shore, MD, FACS.